On October 21, 2015 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that new data on its myRisk Hereditary Cancer molecular diagnostic test will be featured in five presentations at the National Society of Genetic Counselors (NSGC) Annual Conference being held Oct. 21 to 24, 2015 in Pittsburgh, Pa (Press release, Myriad Genetics, OCT 21, 2015, View Source [SID:1234507751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Myriad is a pioneer in translating genetic information into products that save and improve lives. More than ever, we’re dedicated to research that advances the science of hereditary cancer testing for patients now and in the future," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "The data we’re presenting at NSGC this year demonstrate that the myRisk Hereditary Cancer Panel identifies more harmful mutations than testing one gene at a time. Furthermore, as we expand our testing to broader gene panels and identify mutations in genes that have not traditionally been linked to certain family histories, we are challenging the fundamentals of our historical thinking on cancer genetics."

A list of Myriad’s presentations at NSGC (#NSGC2015) follows:

Poster Presentations

Title: Pathogenic mutations identified in patients with 6 or more colon polyps.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.

Location: Poster 55.

Title: Hereditary Cancer Testing in Patients of Ashkenazi Jewish Ancestry in the Era of Panel Testing.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.

Location: Poster 71

Title: Pedigree modeling demonstrates that family history performs poorly for the identification of women with inherited risks for breast cancer.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.

Location: Poster 111.

Title: Outcomes of multi-gene testing for inherited cancer risk in patients of varied ancestries.
Date: Friday, Oct. 23, 2015, 1:15-2:15 p.m. ET.

Location: Poster 72.

Title: Identification of a Recurrent Pathogenic Variant in BRIP1.
Date: Friday, Oct. 23, 2015, 1:15-2:15 p.m. ET.

Location: Poster 74.

For more information about these presentations, including a complete list of posters, please visit the NSGC website at View Source

About Myriad myRisk Hereditary Cancer Testing

The Myriad myRisk Hereditary Cancer test uses next-generation sequencing technology to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: View Source